Text
Rebuilding the R&D engine in big pharma
however, its stock-market record has raised doubts about the sustainability of that history along with fundamental questions about the industry's health. I believe that declining R&D productivity is at the center of its malaise. Some critics question whether so-called Big Pharma can fix its R&D engine. The way to solve the productivity problem is not to break up the pharmaceutical giants into smaller companies. It is to return power to the scientists by reorganizing R&D into small, highly focused groups headed by people who are leaders in their scientific fields and can guide and inspire their teams to achieve greatness. The basic philosophy for modern R&D should be to morph big into small in recognition of the fact that critical mass in fundamental research is the size of one human brain. We have been striving to do all these things at GlaxoSmithKline since 2000, when we began a sweeping reengineering of R&D. Our results to date suggest that we are on the right track.Printed Journal
Ketersediaan
| Call Number | Location | Available |
|---|---|---|
| PSB lt.dasar - Pascasarjana | 1 |
| Penerbit | : Harvard Business School |
|---|---|
| Edisi | - |
| Subjek | Productivity Strategic planning Pharmaceutical industry Business models Research & development R&D |
| ISBN/ISSN | 178012 |
| Klasifikasi | - |
| Deskripsi Fisik | - |
| Info Detail Spesifik | - |
| Other Version/Related | Tidak tersedia versi lain |
| Lampiran Berkas | Tidak Ada Data |